Personalis Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PSNL$15.88-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(81,284) | $(108,296) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 10,686 | 14,051 |
| Depreciation and amortization | 10,941 | 11,296 |
| Noncash operating lease cost | 1,399 | 1,859 |
| Noncash charges related to liability classified Tempus Warrants | 18,274 | 4,027 |
| Amortization of discount on short-term investments | (2,667) | (2,000) |
| Noncash restructuring and other charges | — | 3,605 |
| Noncash lease impairment expense | — | 5,565 |
| Other | 93 | 153 |
| Changes in operating assets and liabilities | ||
| Accounts receivable (1) | 9,590 | (1,088) |
| Inventory and other deferred costs | 4,425 | (1,934) |
| Prepaid expenses and other assets | 1,139 | 3,748 |
| Accounts payable (2) | (8,924) | 5,178 |
| Accrued and other current liabilities (2) | (2,401) | 742 |
| Contract liabilities | (4,116) | 5,952 |
| Operating lease liabilities | (3,505) | 894 |
| Other long-term liabilities (2) | 1,200 | (10) |
| Net cash used in operating activities | (45,150) | (56,258) |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (121,708) | (103,945) |
| Proceeds from maturities of available-for-sale debt securities | 88,000 | 127,955 |
| Purchases of property and equipment | (1,603) | (10,911) |
| Proceeds from sales of property and equipment | 242 | — |
| Net cash (used in) provided by investing activities | (35,069) | 13,099 |
| Cash flows from financing activities: | ||
| Proceeds from sales of common stock under ATM facility, net of commissions | 30,079 | 3,513 |
| Proceeds from issuance of Tempus Warrants | — | 6,000 |
| Proceeds from exercise of Tempus Warrants | 18,438 | — |
| Proceeds from sale of common stock under Tempus Investment Agreement | 17,745 | — |
| Proceeds from sale of common stock under Merck Investment Agreement | 50,000 | — |
| Payment of costs related to Tempus and Merck Investment Agreements | (1,230) | — |
| Proceeds from loans | — | 3,438 |
| Repayments of loans | (1,130) | (3,264) |
| Proceeds from issuance of common stock under equity incentive plans | 770 | 1,344 |
| Net cash provided by financing activities | 114,672 | 11,031 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (22) | (16) |
| Net change in cash, cash equivalents and restricted cash | 34,431 | (32,144) |
| Cash, cash equivalents and restricted cash, beginning of period | 58,774 | 90,918 |
| Cash, cash equivalents and restricted cash, end of period | $93,205 | $58,774 |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $91,415 | $56,984 |
| Restricted cash, included in other long-term assets | 1,790 | 1,790 |
| Total cash, cash equivalents and restricted cash | $93,205 | $58,774 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes, net of refunds | $38 | $64 |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | 473 | 104 |
(1)Includes a change in related party receivable of $2.0 million for the year ended December 31, 2024.
(2)Includes a change in related party payable and accruals of $0.7 million for the year ended December 31, 2024.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.